Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)

Inclusion criteria

• ✓. Provide signed and dated informed consent form
• ✓. Is between 18 and 65 years of age (inclusive; male or female and any race or ethnicity)
• ✓. Meets diagnostic criteria for TMD: Myalgia with or without arthralgia
• ✓. Has experienced facial pain and/or pain with TMJ biomechanics for the last 3 months episodically or unremitting
• ✓. Has experienced facial pain for at least 10 days of the last 30 days prior to Baseline Visit (Visit 0)
• ✓. Prior to randomization, has been compliant 80% with the entries in the Daily Symptom Diary within the baseline period and reported an average pain level ≥30 on a numerical rating scale (0-100) in the DSD, or has experienced a pain level ≥30 on the same scale for at least 3 days in the week prior to Visit 1.
• ✓. If taking a prescription medication daily for the management of pain (taken for at least 30 days before baseline), agrees to continue the daily use of the medication throughout the study at the same dosage.
• ✓. If taking prescription medication, opioid medication or OTC medications as needed or episodically for the management of TMD pain agrees to discontinue its use prior to the Screening and Baseline Visit.

Exclusion criteria